Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2002

View Archived Issues

Coumarin-based compounds as leads for new antiviral agents for measles

Hemolink deemed not approvable by Canadian authorities

Atrix initiates phase II trial of low-dose oral interferon alfa product in oral warts

Isotechnika enters negotiations for drug development agreement

Encouraging phase I results reported for StreptAvax vaccine

Pegasys recommended for approval in E.U. for chronic hepatitis C

Vernalis presents annual progress review

Minimally invasive treatment for GERD safe and effective in long-term human trial

Potent, selective, orally active vasopressin V1b receptor antagonist characterized

Speedel enters agreement with Roche for new class of renin inhibitors

Angiogenic growth factor therapy evaluated for CAD in FIRST trial

Label change for Xenical cleared by CPMP

Efficacy, pharmacokinetic and exposure-response data discussed in Baltimore for pregabalin

Galanin: role in Alzheimer's disease

Remicade granted priority review as Crohn's disease monotherapy

Transition Therapeutics confirms efficacy of interferon combination therapy

Vfend receives marketing approval in Europe for the treatment of fungal infections

Seattle Genetics initiates phase I monoclonal antibody study

Antagonists of human 11CBy receptor claimed for diabetes, depression, etc.

Novel anticoagulants designed at 3-D

Sanofi-Synthelabo reports preparation and use of new benzimidazoles

New PDE5 inhibitors from Almirall Prodesfarma and their use

Recent patent covers Agouron's CDK inhibitors

Inhibitors of fatty acid synthase FabH under study at GSK

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...